ERBB2 and breast carcinoma: The increased mitogen-activated protein kinase (MAPK), phosphatidyl-inositol-3 kinase (PI3K)/AKT and HER3 receptor signaling [58,59], characteristic of HER2+ breast cancers, result in the downstream effects on enhanced cell proliferation and the observed aggressive clinical phenotype.